Tenax Therapeutics, Inc.

These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.

Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.

What management said

“Analysis of the results of the LEVEL trial provides insights into those patients who exhibit a significant improvement in exercise tolerance. With treatment continuing for those randomized prior to October, we believe we have now taken the steps necessary to ensure our LEVEL-2 protocol population will be enriched with these more symptomatic patients,”

Quoted verbatim from the release, and shown only when the filing attributes it to a named person.

How the share price reacted

Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.

What Tenax Therapeutics, Inc. does

(TNX-101, TNX-102, TNX-103) Levosimendan is a novel, first-in-class K-ATP channel activator/calcium sensitizer currently being evaluated to treat pulmonary hypertension (PH) associated with heart failure with preserved ejection fraction (PH-HFpEF). Levosimendan was first developed for intravenous use in hospitalized patients with acutely decompensated heart failure, and it has received market authorization in 60 countries in this indication, although it is not available in the United States or Canada. TNX-103 (oral levosimendan) is being evaluated in LEVEL-2, a Phase 3, double-blind, randomized, placebo-controlled clinical trial in patients with PH-HFpEF.

The company’s own description, as it appears at the foot of the release.